Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects With Atopic Dermatitis
Conditions
Interventions
difelikefalin 0.25 mg
difelikefalin 0.5 mg
+2 more
Locations
40
United States
Cara Therapeutics Study Site
Anniston, Alabama, United States
Cara Therapeutics Study Site
Birmingham, Alabama, United States
Cara Therapeutics Study Site
Scottsdale, Arizona, United States
Cara Therapeutics Study Site
Bryant, Arkansas, United States
Cara Therapeutics Study Site
Fountain Valley, California, United States
Cara Therapeutics Study Site
Lomita, California, United States
Start Date
June 29, 2019
Primary Completion Date
April 1, 2021
Completion Date
April 1, 2021
Last Updated
April 4, 2022
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Cara Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions